Pacific Biosciences of California PACB Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$8.28M+79.5% | -$40.37M-6.2% | -$38M+9.4% | -$41.93M+90.2% | -$426.08M— | ||
| $2.2M-19.6% | $2.74M+11.2% | $2.46M-7.4% | $2.66M-48.2% | $5.13M+80.5% | ||
| $4.46M-53.5% | $9.59M-12.7% | $10.98M-7.7% | $11.9M+29.3% | $9.2M-42.6% | ||
| $0— | —— | —— | —— | -$546K-166% | ||
| $0— | $0— | $0— | $0-100% | $15M— | ||
| -$6.1M-226% | $4.83M— | —— | $612K-85.1% | $4.12M+322% | ||
| $3.21M— | —— | $1.06M-20.5% | $1.33M-47.6% | $2.54M— | ||
| -$4.32M-351% | $1.72M+35.9% | $1.27M+24.1% | $1.02M+167% | -$1.53M-142% | ||
| $314K-93.1% | $4.55M+350% | $1.01M+137% | -$2.72M-974% | $311K— | ||
| $2.29M+419% | -$717K+27.4% | -$988K+70.8% | -$3.38M+1.3% | -$3.43M— | ||
| $5.13M— | —— | -$1.59M+46.7% | -$2.98M-227% | $2.35M— | ||
| -$225K+3.0% | -$232K+41.6% | -$397K-16.8% | -$340K+52.7% | -$719K-144% | ||
| $19K— | —— | —— | —— | $1.33M+145% | ||
| $1.02M+0.1% | $1.02M-0.1% | $1.02M+0.1% | $1.02M-99.7% | $366.39M+5,246% | ||
| $849K-5.0% | $894K-2.9% | $921K+1.9% | $904K-28.1% | $1.26M+0.4% | ||
| $1.43M+3.0% | $1.38M+29.5% | $1.07M+1,054% | -$112K+93.1% | -$1.62M+39.4% | ||
| $0— | $0— | $0— | $0+100% | -$18.7M-859% | ||
| -$44.69M-134% | -$19.07M-1.9% | -$18.71M+36.3% | -$29.38M+33.3% | -$44.06M-43.7% | ||
| $3.04M+253% | $861K— | $0-100% | $550K-60.4% | $1.39M-14.1% | ||
| $52.45M+58.5% | $33.09M-49.7% | $65.83M+17.2% | $56.17M-9.1% | $61.82M-23.2% | ||
| $48.25M— | $0+100% | -$195.45M-338% | $82.01M-27.7% | $113.44M+323% | ||
| $50M— | —— | —— | —— | $0— | ||
| $5M— | —— | —— | —— | $5M— | ||
| $35.86M+37.8% | $26.03M+37.7% | $18.9M-25.2% | $25.28M-44.1% | $45.23M-22.3% | ||
| $1.44M+142% | -$3.43M-333% | $1.47M— | $0-100% | $1.96M— | ||
| $1.44M— | —— | $1.47M— | —— | $1.96M+104% | ||
| -$7.4M-206% | $6.96M+318% | $1.66M+141% | -$4.09M-231% | $3.14M+114% | ||
| —— | $2.07M0.0% | $2.07M0.0% | $2.07M0.0% | $2.07M-44.2% | ||
| $1.02M+0.1% | $1.02M-0.1% | $1.02M+0.1% | $1.02M-99.7% | $366.39M+5,246% | ||
| $0— | $0— | $0— | $0+100% | -$18.7M-859% | ||
| $2.2M-19.6% | $2.74M+11.2% | $2.46M-7.4% | $2.66M-48.2% | $5.13M+80.5% | ||
| $48.1M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $1.43M+3.0% | $1.38M+29.5% | $1.07M+1,054% | -$112K+93.1% | -$1.62M+39.4% | ||
| $2.29M+419% | -$717K+27.4% | -$988K+70.8% | -$3.38M+1.3% | -$3.43M— | ||
| $54K— | $0-100% | $1.23M+38.8% | $883K-88.5% | $7.66M+748% | ||
| $295K-35.9% | $460K-50.2% | $923K-27.7% | $1.28M-25.2% | $1.71M-28.3% | ||
| $849K-5.0% | $894K-2.9% | $921K+1.9% | $904K-28.1% | $1.26M+0.4% | ||
| -$225K+3.0% | -$232K+41.6% | -$397K-16.8% | -$340K+52.7% | -$719K-144% | ||
| $1.9M— | —— | —— | —— | $0— | ||
| $5M— | —— | —— | —— | $5M— | ||
| $48.25M-19.6% | $59.98M-29.1% | $84.64M+3.2% | $82.01M-27.7% | $113.44M-0.1% | ||
| $50M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $1.44M— | —— | $1.47M— | —— | $1.96M— | ||
| $19K— | —— | —— | —— | $1.33M+145% | ||
| $1.43M+3.0% | $1.38M+29.5% | $1.07M+1,054% | -$112K+93.1% | -$1.62M+39.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $0-100% | $25K— | —— | —— | $29.58M— | ||
| -$47.73M-140% | -$19.93M-7.0% | -$18.62M+37.8% | -$29.93M+34.1% | -$45.45M-40.8% | ||
| -$47.73M-140% | -$19.93M-7.0% | -$18.62M+37.8% | -$29.93M+34.1% | -$45.45M-40.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pacific Biosciences of California generate?
- Pacific Biosciences of California (PACB) generated -$111.8M in operating cash flow over the trailing twelve months.
- What is Pacific Biosciences of California's free cash flow?
- After $4.5M of capital expenditures, Pacific Biosciences of California's free cash flow was -$116.2M over the trailing twelve months, up 34.8% year over year.
- Where does Pacific Biosciences of California's cash flow data come from?
- Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
